#1 Clinical Trials Search in Europe

Study Comparing Pevonedistat, Venetoclax, and Azacitidine with Venetoclax and Azacitidine in Adults with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

2 1 1 1

What is this study about?

This clinical trial is focused on studying a treatment for Acute Myeloid Leukemia (AML), a type of cancer that affects the blood and bone marrow. The study is comparing two treatment combinations. One group will receive a combination of three medications: Pevonedistat, Venetoclax, and Azacitidine. The other group will receive two medications: Venetoclax and Azacitidine. Pevonedistat is also known by its code name, MLN4924, and Venetoclax is sometimes referred to as ABT-199 or GDC-0199. Azacitidine is a medication used in various forms, including Azacitidine Mylan and Vidaza.

The purpose of this study is to determine if the combination of Pevonedistat, Venetoclax, and Azacitidine is more effective than the combination of Venetoclax and Azacitidine alone in treating adults with newly diagnosed AML who are not suitable for intensive chemotherapy. Participants in the study will be randomly assigned to one of the two treatment groups. The study will monitor the participants over a period of time to assess the effectiveness and safety of the treatments. The study will also look at how long participants live and how their disease responds to the treatment.

Participants will receive their assigned treatment and will be regularly monitored by healthcare professionals. The study will track various outcomes, including how long it takes for the disease to progress, the overall survival of participants, and the response of the leukemia to the treatment. The study aims to provide valuable information that could improve treatment options for patients with AML who cannot undergo intensive chemotherapy.

1 randomization

Upon joining the study, participants are randomly assigned to one of two groups. This process is called randomization. It ensures that each participant has an equal chance of receiving either the combination of pevonedistat, venetoclax, and azacitidine or just venetoclax and azacitidine.

2 treatment initiation

Participants begin their assigned treatment regimen. Those in the first group receive pevonedistat through an intravenous (IV) infusion. Venetoclax is taken orally in the form of film-coated tablets, and azacitidine is administered either intravenously or subcutaneously (under the skin).

Participants in the second group take venetoclax orally and receive azacitidine either intravenously or subcutaneously.

3 treatment schedule

The treatment is administered in cycles. Each cycle lasts 28 days. The specific dosage and frequency of each medication are determined by the study protocol and the participant’s health condition.

4 monitoring and assessments

Throughout the trial, participants undergo regular health assessments. These include blood tests, physical exams, and other necessary evaluations to monitor the effects of the treatment and ensure safety.

Participants are closely monitored for any side effects or changes in their condition.

5 end of treatment

The treatment continues until the participant completes the study, experiences unacceptable side effects, or the disease progresses.

At the end of the treatment, a final assessment is conducted to evaluate the participant’s response to the therapy.

6 follow-up

After completing the treatment, participants enter a follow-up phase. This involves periodic check-ups to monitor long-term health and any lasting effects of the treatment.

Who Can Join the Study?

  • Patients must be 18 years or older with newly diagnosed Acute Myeloid Leukemia (AML).
  • AML must be confirmed by a doctor using specific criteria.
  • Patients can have different types of AML, including:
    • Primary AML, which is newly diagnosed.
    • Secondary AML, which develops after other blood disorders or treatments.
  • Patients must be considered unfit for intensive chemotherapy due to age or other health issues, such as:
    • Being 75 years or older.
    • Being between 18 and 74 years old with at least one of the following conditions:
      • Poor physical health status (ECOG performance status of 2 or 3).
      • Severe heart problems, like heart failure or angina.
      • Severe lung problems, affecting breathing capacity.
      • Reduced kidney function (creatinine clearance less than 45 mL/min).
      • Liver problems with high bilirubin levels.
  • Laboratory test results must meet specific criteria, such as:
    • Total bilirubin within a certain range, except for patients with Gilbert’s syndrome.
    • Liver enzymes (ALT and AST) within a certain range.
    • Kidney function (creatinine clearance) of at least 30 mL/min.
    • Albumin level greater than 2.7 g/dL.
  • White blood cell count must be less than 25 x 109/L. Patients who have reduced their white blood cell count with certain treatments may still qualify.

Who Cannot Join the Study?

  • Patients who have a different type of cancer other than Acute Myeloid Leukemia (AML) cannot participate.
  • Patients who are fit for intensive chemotherapy are not eligible.
  • Patients who have previously received treatment with the study drugs pevonedistat, venetoclax, or azacitidine are excluded.
  • Patients with uncontrolled or severe heart disease cannot join the study.
  • Patients with active infections that are not controlled are not allowed to participate.
  • Pregnant or breastfeeding women are not eligible for the study.
  • Patients with a history of severe allergic reactions to any of the study drugs are excluded.
  • Patients who have received another investigational drug within a certain period before the study cannot participate.
  • Patients with a history of other serious medical conditions that could interfere with the study are not eligible.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie Cracow Poland
Aksntjm Uhxct Sfmfnwtvc Ldjkvu Dp Bfvdsjp Bologna Italy

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Italy Italy
Not recruiting
19.11.2020
Poland Poland
Not recruiting
19.11.2020

Trial locations

Investigated drugs:

Pevonedistat is an experimental drug being studied for its potential to treat certain types of cancer, including acute myeloid leukemia (AML). It works by blocking a specific protein in cancer cells, which may help stop the growth and spread of these cells. In this trial, pevonedistat is being tested to see if it can improve outcomes for patients with AML who cannot undergo intensive chemotherapy.

Venetoclax is a medication used to treat certain types of blood cancers, including AML. It works by targeting and blocking a protein that helps cancer cells survive. By inhibiting this protein, venetoclax can help kill cancer cells and slow down the progression of the disease. In this study, venetoclax is being used in combination with other treatments to see if it can improve patient outcomes.

Azacitidine is a medication used to treat certain blood disorders and types of leukemia, including AML. It works by interfering with the growth of cancer cells, which can help slow down or stop the progression of the disease. In this clinical trial, azacitidine is being used alongside other medications to evaluate its effectiveness in improving the health of patients with AML who are not suitable for intensive chemotherapy.

Acute Myeloid Leukemia – Acute Myeloid Leukemia is a type of cancer that starts in the blood-forming cells of the bone marrow. It progresses rapidly, leading to the accumulation of immature white blood cells called myeloblasts. These cells crowd out normal blood cells, causing symptoms like fatigue, frequent infections, and easy bruising or bleeding. As the disease advances, it can spread to other parts of the body, including the lymph nodes, liver, and spleen. The rapid progression of the disease requires prompt medical attention to manage its effects.

Trial ID:
2024-515424-36-00
Protocol code:
Pevonedistat-2002
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +7

  • A Study Comparing Two Treatment Schedules of Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Suitable for Intensive Treatment

    Recruiting

    3 1 1 1
    Investigated drugs:
    France Spain